by Clinical Neuropsychologist | Monday, November 18, 2024 | Dementia
Abstract INTRODUCTION Cardiovascular drug use may help prevent dementia; however, current evidence is mixed. Using a case–control design, we investigated the association between duration and combination of multiple cardiovascular drug classes and incident dementia....
by Clinical Neuropsychologist | Thursday, November 14, 2024 | Dementia
Abstract INTRODUCTION We investigated the effects of multiple cerebrovascular disease (CeVD) neuroimaging markers on brain functional connectivity (FC), and how such CeVD-related FC changes interact with plasma phosphorylated tau (p-tau)181 (an Alzheimer’s...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION We aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)-independent or Aβ-dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET)....
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Interventions to treat speech-language difficulties in primary progressive aphasia (PPA) often use word accuracy as a highly comparable outcome. However, there are more constructs of importance to people with PPA that have received less...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer’s Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. This...
by Clinical Neuropsychologist | Wednesday, November 13, 2024 | Dementia
Abstract INTRODUCTION Pathological and neuroimaging alterations in the cerebellum of Alzheimer’s disease (AD) patients have been documented. However, the role of cerebellum-derived radiomic and structural connectome modeling in the prediction of AD progression...
